Formulation and In-Vitro Evaluation of Enteric Coated Tablet Incorporating Rabeprazole

  • Gautam D. Mehetre Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India
  • Rameshwar S. Cheke Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India
  • Vinayak N. Shrikhande Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

Abstract

The objective of the work is to try and assess the applicability and manufacturing possibilities to optimize an enteric coated tablet formulation containing Rabeprazole sodium as the drug aiming at the anti-acidity activity with desired drug release properties. Enteric coated tablet was chosen as dosage form being a cost-effective technology for pharmaceutical industry requiring fewer procedures. Before the implementation of the pharmaceutical technological aims, analysis of critical factors influencing the manufacture was carried out. Reproducible manufacturing processes are required to achieve suitability and tablets uniformity to achieve the uniform properties of tablets, which could influence experimental parameters. Rabeprazole in core content of tablet is blended with HPMC (different grades), xanthan gum, PVPK30, mannitol, crosspovidone, Sodium starch glycolate, Colloidal silicon dioxide to formulate the product. Prepared formulation was tested for weight and content uniformity, physical characteristics, in vitro dissolution behaviour, acid resistance and accelerated stability studies. All studies performed resulted and revealed for assurance of such enteric coated tablet formulation for drug Rabeprazole with optimum characteristics, concluding it as a promising approach to enhance drug release characteristics.


Keywords: Rabeprazole, HPMC, enteric coated tablets, In Vitro evaluation.

Keywords: Rabeprazole, HPMC, enteric coated tablets, In Vitro evaluation

Downloads

Download data is not yet available.

Author Biographies

Gautam D. Mehetre, Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

Rameshwar S. Cheke, Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

Department of Pharmaceutics, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

Vinayak N. Shrikhande, Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist- Buldana, 443101 Maharashtra, India

References

1. Robinson JR, Lee VH, In: Controlled Drug Delivery Fundamentals and Applications, Marcel Dekker, INC, New York, 1987; Vol. 29, 2nd edition, 4-6.
2. Tripathi KD, Pharmacological classification of drugs, 2005; 3rd edition, 18.
3. Swarbrick J, Encyclopaedia of Pharmaceutical Technology, Vol.1, 3rd edition, 1248-1250.
4. Fukui E, Miyamura N, Uemura K et al. Preparation of enteric-coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting, International Journal Pharmaceutics, 2000; 204, 7-15.
5. Yong CS, Jung JH, Rhee JD, Kook KC, Choi HG, Preformulation studies of tablets, Drug Development in Industrial Pharmacy, 2001; 27(5): 447–455.
6. Sweetman SC, Martindale- The Complete Drug Reference, Pharmaceutical Press, Landon, 2005; 256-258.
7. Hunt RH, Armstrong D, Yaghoobi M, James C, The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. Esomeprazole 40 mg in healthy male subjects, Aliment Pharmacology Therapy, 2010; 31:648–657.
8. Raymond CR, Paul JS, Quinn ME, Hand Book of Pharmaceutical Excipients, Pharmaceutical Press, Washington D.C., 2009; 6th edition, 581-585.
9. Raymond CR, Paul JS, and Quinn ME, Hand Book of Pharmaceutical Excipients, Pharmaceutical Press, Washington D.C., 2009; 6th edition, 404-407.
10. Remington's Pharmaceutical Sciences, The Science and Practice of Pharmacy, Mack Publishing Company, Vol. 1, 19th edition, 1669-1670.
11. Hoogerwerf WA, Pasricha PJ, In: Hardman, JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, International Publication McGraw Hill, New York, 1996; 1007-1009.
12. Lachman L, Liberman HA, Kanig JL, The Theory and Practice of Industrial Pharmacy, 3rd edition, 3rd Indian Reprint, Varghese Publishing House, Bombay, 1990; 316-317.
13. Laine L, Katz PO, Johnson DA, et al. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive esophagitis – the results of two double-blind studies, Aliment Pharmacology Therapy, 2011; 33:203–212.
14. Brirish Pharmacopoeia, Volume III, 2009; Formulated Preparations: Specific monographs, Tablets, 1.
15. Biswas BK, Islam S, Begum F, et al. In vitro release kinetic study of esomeprazole magnesium from methocel K15M and methocel K100M LVCR matrix tablets, Dhaka University Journal of Pharmaceutical Sciences, 2008; 7:39-45.
16. Murthy KS, Kubert DA, Fawzi MB, In vitro release characteristics of hard shell capsule products coated with aqueous- and organic-based enteric polymers, Journal of Biomater Applications, 1988; 3:52-79.
17. Sinha VR, Kumria R, Coating polymers for colon specific drug delivery: A comparative in vitro evaluation, Acta Pharma, 2003; 53:41-47.
18. Johnson DA, Review of esomeprazole in the treatment of acid disorders, Expert Opinions in Pharmacotherapy, 2003; 4:253-264.
19. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG, Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis, Aliment Pharmacology Therapy, 2007; 25:617–628.
20. Yuan Y, Hunt RH, Rabeprazole extended release 50 mg compared with esomeprazole 40 mg and rabeprazole delayed release 20 mg, Aliment Pharmacology Therapy, 2011; 33:1177.
21. Morelli G, Chen H, Rossiter G, Rege B, Lu Y, An open-label, parallel, multiple- dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers, Aliment Pharmacology Therapy, 2011; 33:845–854.
22. Aulton ME, Pharmaceutics: The Science of Dosage form design, Churchill Livingstone, England, 2002; 2nd edition, 247.
23. Jain R, Jindal C, Singh S, Pharmaceutical composition comprising of proton pump inhibitor and prokinetic agent, U. S. Patent No 2007/0160664A1, 2007.
24. Aoki S, Preparation, composition containing acid unstable physiologically active compound and process for producing same, U. S. Patent No. US 2005/0163846 A1, 2005.
Statistics
322 Views | 477 Downloads
How to Cite
1.
Mehetre GD, Cheke RS, Shrikhande VN. Formulation and In-Vitro Evaluation of Enteric Coated Tablet Incorporating Rabeprazole. JDDT [Internet]. 15Apr.2020 [cited 18Aug.2022];10(2-s):50-7. Available from: http://jddtonline.info/index.php/jddt/article/view/3953